Analysts See $-0.05 EPS for Theratechnologies Inc. (TH)

March 15, 2018 - By Winifred Garcia

 Analysts See $ 0.05 EPS for Theratechnologies Inc. (TH)

Analysts expect Theratechnologies Inc. (TSE:TH) to report $-0.05 EPS on April, 5.They anticipate $0.02 EPS change or 66.67 % from last quarter’s $-0.03 EPS. After having $-0.06 EPS previously, Theratechnologies Inc.’s analysts see -16.67 % EPS growth. The stock increased 0.81% or $0.08 during the last trading session, reaching $9.94. About 266,014 shares traded or 80.46% up from the average. Theratechnologies Inc. (TSE:TH) has 0.00% since March 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Theratechnologies Inc. (TSE:TH) Ratings Coverage

Among 2 analysts covering Theratechnologies Inc. (TSE:TH), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Theratechnologies Inc. had 6 analyst reports since February 25, 2016 according to SRatingsIntel. National Bank Canada downgraded the shares of TH in report on Friday, November 11 to “Outperform” rating.

Theratechnologies Inc., specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and an enhanced life among HIV patients. The company has market cap of $745.27 million. The Company’s lead product is EGRIFTA, which increases the incidence or progression of diabetic retinopathy in diabetic HIV-infected patients with lipodystrophy and excess abdominal fat in the United States and Canada. It currently has negative earnings.

More notable recent Theratechnologies Inc. (TSE:TH) news were published by: which released: “Theratechnologies Announces New Findings with the Investigational …” on July 24, 2017, also with their article: “Theratechnologies Announces Results from the Last Pivotal Phase III Trial of …” published on November 10, 2016, published: “Theratechnologies Announces Financial Results for Second Quarter of 2017” on July 12, 2017. More interesting news about Theratechnologies Inc. (TSE:TH) were released by: and their article: “Theratechnologies Announces Financial Results for Fiscal Year 2017” published on February 07, 2018 as well as‘s news article titled: “Theratechnologies, Taimed get FDA nod, and several firsts, for HIV drug” with publication date: March 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: